Virus Res, 2023, 334:199158

Antiviral Activity of Singlet Oxygen-Photogenerating Perylene Compounds Against SARS-CoV-2: Interaction with the Viral Envelope and Photodynamic Virion Inactivation

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has prompted great interest in novel broad-spectrum antivirals, including perylene-related compounds. In the present study, we performed a structure-activity relationship analysis of a series of perylene derivatives, which comprised a large planar perylene residue, and structurally divergent polar groups connected to the perylene core by a rigid ethynyl or thiophene linker. Most of the tested compounds did not exhibit significant cytotoxicity towards multiple cell types susceptible to SARS-CoV-2 infection, and did not change the expressions of cellular stress-related genes under normal light conditions . These compounds showed nanomolar or sub-micromolar dose-dependent anti-SARS-CoV-2 activity, and also suppressed the in vitro replication of feline coronavirus (FCoV), also termed feline infectious peritonitis virus (FIPV). Perylene compounds exhibited high affinity for liposomal and cellular membranes, and efficiently intercalated into the envelopes of SARS-CoV-2 virions, thereby blocking the viral-cell fusion machinery. Furthermore, the studied compounds were demonstrated to be potent photosensitizers, generating reactive oxygen species (ROS), and their anti-SARS-CoV-2 activities were considerably enhanced after irradiation with blue light. Our results indicated that photosensitization is the major mechanism underlying the anti-SARS-CoV-2 activity of perylene derivatives, with these compounds completely losing their antiviral potency under red light. Overall, perylene-based compounds are broad-spectrum antivirals against multiple enveloped viruses, with antiviral action based on light-induced photochemical damage (ROS-mediated, likely singlet oxygen-mediated), causing impairment of viral membrane rheology.

Straková P, Bednář P, Kotouček J, Holoubek J, Fořtová A, Svoboda P, Štefánik M, Huvarová I, Šimečková P, Mašek J, Gvozdev DA, Mikhnovets IE, Chistov AA, Nikitin TD, Krasilnikov MS, Ustinov AV, Alferova VA, Korshun VA, Růžek D, Eyer L

IBCH: 10736
Ссылка на статью в журнале: https://doi.org/10.1016/j.virusres.2023.199158
Кол-во цитирований на 02.2024: 5
Данные статьи проверены модераторами 2023-07-31

Список научных проектов, где отмечена публикация

  1. LX22NPO5103. . Сommercial.
  2. Development of means of prevention and treatment of COVID-19 and concomitant infectious diseases using genetic technologies (September 28, 2021 — December 31, 2023). Gabibov A.G., Andreev D.E., Aralov A.V., Bezuglov V.V., Belogurov A.A., Vodovozova E.L., Zvyagin A.V., Konstantinova I.D., Korshun V.A., Ovchinnikova T.V., Rubcov Y.P., Smirnov I.V., Tonevickiy A.G.. Agreement / contract, Ministry of Science.